BioLineRx Ltd. (NASDAQ:BLRX – Get Free Report) saw a large growth in short interest during the month of September. As of September 15th, there was short interest totalling 179,200 shares, a growth of 28.7% from the August 31st total of 139,200 shares. Based on an average daily volume of 270,600 shares, the short-interest ratio is presently 0.7 days.
Hedge Funds Weigh In On BioLineRx
An institutional investor recently bought a new position in BioLineRx stock. PVG Asset Management Corp acquired a new stake in shares of BioLineRx Ltd. (NASDAQ:BLRX – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 61,840 shares of the biotechnology company’s stock, valued at approximately $97,000. BioLineRx accounts for approximately 0.5% of PVG Asset Management Corp’s holdings, making the stock its 29th largest holding. PVG Asset Management Corp owned 0.09% of BioLineRx as of its most recent SEC filing. 1.56% of the stock is owned by institutional investors.
BioLineRx Trading Down 1.6 %
Shares of NASDAQ:BLRX traded down $0.01 during midday trading on Friday, reaching $0.62. The company’s stock had a trading volume of 145,924 shares, compared to its average volume of 333,238. The firm has a market cap of $49.56 million, a price-to-earnings ratio of -0.82 and a beta of 1.46. The business has a 50 day moving average price of $0.69 and a 200 day moving average price of $0.72. BioLineRx has a 1 year low of $0.51 and a 1 year high of $2.03. The company has a quick ratio of 1.49, a current ratio of 1.61 and a debt-to-equity ratio of 1.34.
Analyst Ratings Changes
Separately, StockNews.com upgraded shares of BioLineRx from a “sell” rating to a “hold” rating in a research report on Monday, June 3rd.
View Our Latest Research Report on BLRX
About BioLineRx
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.
Further Reading
- Five stocks we like better than BioLineRx
- What Are Some of the Best Large-Cap Stocks to Buy?
- CarMax’s Impressive Rally: What Investors Should Watch Next
- EV Stocks and How to Profit from Them
- MarketBeat Week in Review – 9/23 – 9/27
- How Investors Can Find the Best Cheap Dividend Stocks
- Wake Up to This Biotech Stock That Still Has Big Potential Upside
Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.